APBI: code changes
As part of new requirements, pharma firms will need to make publicly available a short description of any financial and indirect support for patient organisations that they provide.

Companies are also encouraged to publish information about donations and grants to institutions that support healthcare and research. Sponsorship declarations must also accurately reflect the nature of a pharma company's involvement.

Changes include heightening awareness of the need for health professionals to report adverse drug reactions.

In the wake of recent press concerning clinical trials, the pharma industry will now be in breach of the code if they fail to disclose details on any ongoing clinical trials.

PR relevant changes include more guidance about meetings and hospitality.

The changes have been approved by the ABPI and will come into effect on 1 July.The code is being revised following changes made to the European Federation of Pharmaceutical Industries and Associations code last year.